Related coverage linked through entity extraction aliases.
May 01, 2026
Ray Therapeutics received EMA PRIME designation for its RTx-015 optogenetic gene therapy for retinitis pigmentosa, following recent FDA RMAT status. The company also appointed Michael Murtagh as Chief Regulatory Officer to support global development.
Mar 18, 2026
Researchers have developed advanced platforms to study human neural networks, including 3D bioelectronics for brain organoids and scalable 2D neuron networks that reveal brain-like rhythms and drug responses.
Feb 13, 2026
BridgeBio Pharma reported positive Phase 3 results for oral infigratinib in children with achondroplasia, meeting primary and secondary endpoints with superior growth velocity and the first statistically significant improvement in body proportionality. The company plans regulatory submissions in the second half of 2026.
